Overview
Tirzepatide is classified as a dual agonist (glp-1/gip) peptide. Weight loss, body recomposition, glycemic control.
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Also known as: Mounjaro, Zepbound
Category
Dual Agonist (GLP-1/GIP)
Half-Life
120h
Route
SubQ
FDA Status
Approved
How Does Tirzepatide Work?
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
At the molecular level, Tirzepatide operates through pathways characteristic of the Dual Agonist (GLP-1/GIP) class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Tirzepatide Phase 3 SURMOUNT-1: up to 22.5% weight loss
Jastreboff et al. (NEJM): Phase 3 SURMOUNT-1 trial tirzepatide 15mg achieved 22.5% body weight reduction vs 2.4% placebo at 72 weeks in 2,539 adults with obesity.
Evidence: very strong[2]SURMOUNT-4: 176-week long-term weight maintenance
Aronne et al.: 176-week data showing sustained weight loss maintenance with continued tirzepatide treatment 15mg dose maintained -19.7% weight reduction.
Evidence: very strong[3]Tirzepatide meta-analysis: BMI, weight, and metabolic outcomes
Meta-analysis of multiple RCTs confirming tirzepatide significantly reduces BMI, waist circumference, body weight, and HbA1c across diverse patient populations.
Evidence: very strong[4]SURPASS program: tirzepatide in type 2 diabetes (Phase 3)
Frias et al. (NEJM): SURPASS-1 trial showing tirzepatide reduces HbA1c by up to 2.07% and body weight by 9.5 kg in type 2 diabetes. Superior to semaglutide in head-to-head trials.
Evidence: very strong[5]Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
A study published in Lancet (London, England) investigating the effects and mechanisms.
Evidence: moderate[6]Tirzepatide for Obesity Treatment and Diabetes Prevention.
A study published in The New England journal of medicine investigating the effects and mechanisms.
Evidence: preclinical[7]Obesity Management in Adults: A Review.
A study published in JAMA investigating the effects and mechanisms.
Evidence: moderate[8]Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
A study published in The New England journal of medicine investigating the effects and mechanisms.
Evidence: moderate[9]Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
A study published in JAMA investigating the effects and mechanisms.
Evidence: moderate[10]Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
A study published in American heart journal investigating the effects and mechanisms.
Evidence: preclinical[11]Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
A study published in Nature medicine investigating the effects and mechanisms.
Evidence: moderate[12]Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
A study published in The New England journal of medicine investigating the effects and mechanisms.
Evidence: preclinical[13]Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
A study published in Lancet (London, England) investigating the effects and mechanisms.
Evidence: moderate[14]Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
A study published in The New England journal of medicine investigating the effects and mechanisms.
Evidence: preclinical[15]Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
A study published in JAMA internal medicine investigating the effects and mechanisms.
Evidence: preclinical[16]Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
A study published in JAMA investigating the effects and mechanisms.
Evidence: moderate[17]Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
A study published in The New England journal of medicine investigating the effects and mechanisms.
Evidence: preclinical[18]Tirzepatide: A Systematic Update.
A study published in International journal of molecular sciences investigating the effects and mechanisms.
Evidence: preclinical[19]Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial.
A study published in Contemporary clinical trials investigating the effects and mechanisms.
Evidence: moderate[20]Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.
A study published in Frontiers in endocrinology investigating the effects and mechanisms.
Evidence: preclinicalSafety Profile
FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). GI side effects common but manageable. Well-studied long-term safety.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~25–33% (dose-dependent) | moderate |
| Diarrhea | ~19–23% (dose-dependent) | mild |
| Vomiting | ~9–13% (dose-dependent) | moderate |
| Constipation | ~11–18% (dose-dependent) | mild |
| Hypoglycemia | ~5% of users | moderate |
Sourcing Tirzepatide for Research
If you're looking to source Tirzepatide for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Tirzepatide — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.